Akebia: Vafseo approved in Australia; Auryxia 2023 revenue guidance lowered to $170-175M

Akebia Therapeutics, Inc.

Australia's TGA approved Vafseo (vadadustat) for anemia in dialysis patients; product now approved in 35 countries.
Akebia lowered Auryxia net product revenue guidance for 2023 to $170-175M from $175-180M due to market dynamics.
Company plans to resubmit U.S. NDA for vadadustat by end of Q3 2023.
Appointed Graham Ray (ex-Takeda) as VP, Key Accounts to lead U.S. launch prep and customer engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.